Table 3. Incidence of ESRD and hospitalization for CHF in 1513 patients with type 2 diabetes and overt nephropathy according to NKF stages and randomization to losartan or placebo treatmenta

NKF StageGFR (ml/min per 1.73 m2)No. of PatientsESRD on Losartan (%)ESRD on Placebo (%)Risk Reduction (%; 95% CI)P (Losartan versus Placebo)CHF on Losartan (%)CHF on Placebo (%)Risk Reduction (%; 95% CI)P (Losartan versus Placebo)
Stage I (GFR ≥90 ml/min per 1.73 m2) and stage V (GFR <15 ml/min per 1.73 m2) were not considered because they included only 0 and 1 patient, respectively. CHF, congestive heart failure; CI, confidence interval.
II60–89951 (2.7)6 (10.3)82 (−64 to 98)0.135 (13.5)5 (8.6)−42 (−400 to 60)0.58
III30–59103064 (12.1)87 (17.3)33 (8 to 52)0.0255 (10.4)71 (14.1)29 (−1 to 50)0.06
IV15–2938781 (43.6)101 (50.3)23 (−4 to 43)0.0829 (15.6)50 (24.9)41 (6 to 63)0.03